Spinal cord lesions in multiple sclerosis: symptoms, MRI diagnosis and modern treatment (2026)
A complete guide to spinal MS lesions: why they cluster in the cervical and thoracic cord, how they appear on MRI, the 4 main symptom groups they cause (motor, sensory, bladder/bowel, Lhermitte), when they signal disease progression, and which modern therapies — from steroids and DMTs to rehabilitation — slow the damage.
What are spinal cord lesions in MS
Readers ask me about this often, so I have put the practical points together in one place. Multiple sclerosis attacks myelin — the protective sheath around nerve fibres — in the white matter of the central nervous system. When this happens in the spinal cord, spinal lesions (demyelinating plaques) form. The spinal cord is a narrow "motorway" carrying every motor and sensory signal below the head, so even small lesions can cause large symptoms — much larger than lesions of the same size in the brain [1](#ref-1).
Studies show that around 80% of people with MS have at least one spinal cord lesion during their disease, and the proportion is even higher in primary progressive (PPMS) and secondary progressive (SPMS) forms [2](#ref-2)[3](#ref-3). Spinal cord lesions are one of the strongest predictors of disability — better than lesion count in the brain.
Where they most often appear
The spinal cord is anatomically divided into 4 regions: cervical (neck, C1–C8), thoracic (T1–T12), lumbar and sacral. In MS, lesions most commonly appear in:
- Cervical cord (65–75% of cases) — especially the upper cervical segments (C2–C4). These lesions cause the most striking symptoms because every motor and sensory tract passes through here.
- Thoracic cord (25–35%) — often "silent" lesions found only on MRI, but they can cause the "MS hug" (dysaesthesia thoracica).
- Conus and lumbar cord — rare in MS; when present, other diagnoses (NMOSD, MOGAD, other myelitis) must be ruled out.
Typical MS lesions are short (< 2 vertebral bodies in length), peripheral (on the edge of the cross-section) and asymmetric — which distinguishes them from the longer, central lesions seen in neuromyelitis optica (NMOSD) and acute transverse myelitis [4](#ref-4).
main symptoms of spinal lesions
Motor weakness and spasticity
The most common symptom. Damage to the corticospinal tract in the spinal cord interrupts signals travelling from the brain to the leg and arm muscles. The result: weakness in one or both legs, difficulty lifting the foot ("foot drop"), falls when walking, a "scissor gait" from adductor spasticity. Up to 80% of people with MS develop some form of spasticity, most often caused by spinal plaques — see our [spasticity guide](/en/blog/ms-spasticity-muscle-spasms-complete-guide-causes-medication-exercises) [5](#ref-5).
Sensory disturbances and the "MS hug"
Numbness, tingling, pins-and-needles and a "walking on cotton" feeling in legs and feet. A hallmark of thoracic lesions is dysaesthesia thoracica or the "MS hug" — the sensation of a tight belt or corset around the torso, as though something is constantly squeezing the ribs. It scares patients because it mimics cardiac problems, but it is caused by lesions in T3–T8. More: [the MS hug — dysaesthesia thoracica](/en/blog/ms-hug-dysesthesia-thoracica).
Bladder, bowel and sexual dysfunction
The sacral parasympathetic centres that control the bladder, bowel and erectile/lubricatory function receive their signals through the spinal cord. Lesions in the cervical or upper thoracic cord interrupt this pathway, causing:
- Overactive or underactive bladder — urgency, frequency, incontinence, or the opposite — urinary retention with high residual volume (a risk factor for infection). See [MS bladder dysfunction](/en/blog/bladder-dysfunction-ms-overactive-retention).
- Constipation or urgent faecal incontinence.
- Erectile dysfunction in men, reduced lubrication and sensation in women. See [MS and male sexual health](/en/blog/can-ms-cause-erectile-dysfunction-complete-guide-men-multiple-sclerosis) and [female sexual health](/en/blog/how-ms-affects-women-s-sexual-health-complete-guide).
Lhermitte's sign and neuropathic pain
The classic sign of cervical cord lesions: bending the head forward toward the chest triggers a brief "electric shock" that shoots down the spine and legs. It lasts seconds and is triggered by mechanical stretch of demyelinated fibres inside the dural sac. It is not dangerous but is a marker of an active cervical lesion. Chronic neuropathic pain is common alongside — burning, unexplained cold sensations, allodynia (pain on light touch).
MRI: the gold standard
MRI of the spinal cord is the only reliable way to see spinal lesions. Whenever MS is suspected or new neurological symptoms appear, neurologists order:
T2 sequences — lesions appear as bright (hyperintense) spots. STIR sequences — improve contrast and help distinguish MS lesions from artefacts. T1 with gadolinium — highlights active (Gd+) lesions where the blood-brain barrier is disrupted. An active lesion means inflammation is happening right now.
Under the 2024 McDonald criteria, at least one spinal cord lesion counts as one of the five anatomical regions that establish "dissemination in space" — which, combined with "dissemination in time", supports the diagnosis of MS [6](#ref-6). More: [MRI and multiple sclerosis — what doctors see](/en/blog/what-doctors-look-mri-scans-multiple-sclerosis-detailed-guide).
Practical tip: at the time of diagnosis always request MRI of the brain AND the whole spinal cord (cervical + thoracic). Up to 20% of MS patients have isolated spinal cord lesions with no new brain changes, so a partial scan misses the diagnosis [7](#ref-7).
When spinal lesions mean progression
Spinal lesions are the strongest MRI marker of long-term disability in MS. Longitudinal studies show:
- People with ≥ 2 cervical lesions on the first MRI have a 3- to 4-fold higher risk of developing secondary progressive MS within 15 years [8](#ref-8).
- Cervical cord atrophy correlates with EDSS score better than brain atrophy [9](#ref-9).
- In PPMS, spinal lesions are more often "expanded", occupy a larger part of the cross-section, and show diffuse atrophy.
That is why neurologists routinely monitor the cord — usually annual MRI in active disease.
Differential diagnosis — not always MS
Long lesions (> 3 vertebral bodies, "longitudinally extensive transverse myelitis") are not typical for MS and must be distinguished from:
NMOSD (Devic's disease) — anti-AQP4 antibodies, long central lesions, usually more severe attacks. MOGAD — anti-MOG antibodies, similar myelitis but different course and treatment. Spinal cord vascular disease, sarcoidosis, B12 deficiency, HTLV-1 myelopathy.
Treating these conditions with MS therapy can worsen the patient — so every spinal myelitis case should be tested for anti-AQP4 and anti-MOG antibodies.
How lesions are treated
Acute relapse
When a new symptomatic lesion appears (a relapse), the standard treatment is a corticosteroid pulse: methylprednisolone 1 g intravenously daily for 3–5 days, optionally continued with oral prednisone. In severe steroid-refractory attacks — plasma exchange (5–7 sessions) at a tertiary centre. More: [how to recognise and treat a relapse](/en/blog/how-recognise-ms-relapse-checklist-symptom-diary-call-neurologist).
Long-term — DMTs
The foundation of preventing new lesions is disease-modifying therapy (DMT). In active spinal MS with frequent relapses or heavy lesion load, high-efficacy therapy from the start ("hit hard and early") is increasingly preferred over stepwise escalation:
- Anti-CD20 monoclonal antibodies — [Ocrevus (ocrelizumab)](/en/blog/ocrevus-ocrelizumab-complete-2026-guide-works-efficacy-safety-access-ms), [Kesimpta (ofatumumab)](/en/blog/kesimpta-ofatumumab-complete-2026-guide-works-efficacy-self-injection-ms) — strongest evidence for reducing new spinal lesions.
- [Tysabri (natalizumab)](/en/blog/tysabri-natalizumab-complete-2026-guide-works-affirm-efficacy-pml-risk-ms) — very effective, but carries a PML risk in JC-positive patients.
- [Mavenclad (cladribine)](/en/blog/mavenclad-cladribine-complete-2026-guide-short-oral-course-long-term-ms) — oral "reset" therapy in two short courses.
- Platform therapies — [Tecfidera](/en/blog/tecfidera-dimethyl-fumarate-complete-2026-guide-works-define-confirm-ms), [Copaxone](/en/blog/copaxone-glatiramer-acetate-complete-2026-guide-works-gala-efficacy-ms), interferons — still useful in milder forms.
- For progressive forms — Ocrevus (the only agent approved for PPMS), with newer BTK inhibitors such as tolebrutinib on the way. See [DMTs in 2026](/en/blog/latest-ms-drugs-approved-2025-2026-cenrifki-tolebrutinib-pediatric).
Symptomatic therapy and rehabilitation
Lesions cannot be "erased", but symptoms can be dramatically reduced:
- Spasticity — baclofen, tizanidine, gabapentin, botulinum toxin, and an intrathecal baclofen pump in severe cases.
- Bladder — antimuscarinics (solifenacin, tolterodine), mirabegron, clean intermittent catheterisation (CIC) for retention. See [catheterisation — a practical guide](/en/blog/catheterisation-multiple-sclerosis-needed-done-which-catheter-choose).
- Neuropathic pain — gabapentin, pregabalin, duloxetine, carbamazepine (especially for trigeminal neuralgia).
- Physiotherapy and exercise — stretching, aquatic therapy at 27–29°C, FES electrical stimulation for foot drop, robotic gait training. See [exercises by EDSS level](/en/vezbe).
- Orthoses — AFO (ankle-foot orthosis) for foot drop and other assistive devices as needed.
When to see a neurologist immediately
New or rapidly worsening leg/arm weakness lasting > 24h. Sudden urinary retention (inability to urinate) or new incontinence. A new "MS hug" or Lhermitte's sign that was not there before. Sudden loss of sensation below a specific body level ("sensory level") — this may be transverse myelitis and requires EMERGENCY assessment.
The rule is simple: a new symptom + lasting > 24h + no fever or infection = see a neurologist the same day.
Practical action plan
1. Insist on MRI of the brain AND the whole spinal cord at diagnosis and every follow-up.
2. Do not skip your annual MRI even if you feel stable — "silent" lesions do happen.
3. Keep a symptom diary (bladder, spasticity, Lhermitte, new pain) and show it to your neurologist.
4. Do not interrupt DMT — every new lesion means permanent axonal loss.
5. Involve a physiotherapist early — even at EDSS 0–2, regular physiotherapy preserves strength and balance.
6. Suspected relapse — call your neurologist the same day; corticosteroids work best in the first 2 weeks.
7. Rule out pseudo-relapse (UTI, heat, fatigue) before any treatment escalation. See [why MS symptoms worsen in the heat](/en/blog/why-ms-symptoms-get-worse-hot-weather-science-protect-yourself).
In summary
Spinal lesions are often the "invisible" but most impactful part of MS — they largely determine walking, bladder function and long-term disability. Early and accurate MRI (brain + whole spine), the right DMT and lifelong rehabilitation form a combination that in 2026 can dramatically slow disease progression in most patients. Whenever a new symptom lasts longer than 24 hours — do not wait, contact your neurologist.
Sources and evidence
1. {#ref-1} Kearney H, Miller DH, Ciccarelli O. *Spinal cord MRI in multiple sclerosis — diagnostic, prognostic and clinical value.* Nat Rev Neurol. 2015;11(6):327–338. [DOI: 10.1038/nrneurol.2015.80](https://doi.org/10.1038/nrneurol.2015.80).
2. {#ref-2} Bot JC, Barkhof F, Polman CH, et al. *Spinal cord abnormalities in recently diagnosed MS patients.* Neurology. 2004;62(2):226–233. [DOI: 10.1212/wnl.62.2.226](https://doi.org/10.1212/wnl.62.2.226).
3. {#ref-3} Lycklama G, Thompson A, Filippi M, et al. *Spinal-cord MRI in multiple sclerosis.* Lancet Neurol. 2003;2(9):555–562. [DOI: 10.1016/s1474-4422(03)00504-0](https://doi.org/10.1016/s1474-4422(03)00504-0).
4. {#ref-4} Wingerchuk DM, Banwell B, Bennett JL, et al. *International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.* Neurology. 2015;85(2):177–189. [DOI: 10.1212/WNL.0000000000001729](https://doi.org/10.1212/WNL.0000000000001729).
5. {#ref-5} Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. *Prevalence and treatment of spasticity reported by MS patients.* Mult Scler. 2004;10(5):589–595. [DOI: 10.1191/1352458504ms1085oa](https://doi.org/10.1191/1352458504ms1085oa).
6. {#ref-6} Montalban X, et al. *2024 revisions to the McDonald diagnostic criteria for multiple sclerosis.* Lancet Neurol. 2024 — updated diagnostic framework including the spinal cord as an anatomical region.
7. {#ref-7} Sombekke MH, Wattjes MP, Balk LJ, et al. *Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis.* Neurology. 2013;80(1):69–75. [DOI: 10.1212/WNL.0b013e31827b1a67](https://doi.org/10.1212/WNL.0b013e31827b1a67).
8. {#ref-8} Brownlee WJ, Altmann DR, Prados F, et al. *Early imaging predictors of long-term outcomes in relapse-onset MS.* Brain. 2019;142(8):2276–2287. [DOI: 10.1093/brain/awz156](https://doi.org/10.1093/brain/awz156).
9. {#ref-9} Casserly C, Seyman EE, Alcaide-Leon P, et al. *Spinal cord atrophy in multiple sclerosis: a systematic review and meta-analysis.* J Neuroimaging. 2018;28(6):556–586. [DOI: 10.1111/jon.12553](https://doi.org/10.1111/jon.12553).
10. {#ref-10} MyMSTeam. *4 Symptoms Caused by MS Spinal Lesions: How Common Are They?* (2026). [mymsteam.com/resources/multiple-sclerosis-spine-lesions-your-guide](https://www.mymsteam.com/resources/multiple-sclerosis-spine-lesions-your-guide).
*This article is educational and does not replace neurology advice. If new or worsening symptoms appear, contact your doctor.*